Abstract
Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
CNS & Neurological Disorders - Drug Targets
Title:Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa
Volume: 13 Issue: 6
Author(s): Alexandre R. de Mello Schier, Natalia P. de Oliveira Ribeiro, Danielle S. Coutinho, Sergio Machado, Oscar Arias-Carrion, Jose A. Crippa, Antonio W. Zuardi, Antonio E. Nardi and Adriana C. Silva
Affiliation:
Keywords: Anxiety, anxiolytic-like, cannabis sativa, cannabidiol, CBD, major depression.
Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.
Export Options
About this article
Cite this article as:
Schier R. de Mello Alexandre, Ribeiro P. de Oliveira Natalia, Coutinho S. Danielle, Machado Sergio, Arias-Carrion Oscar, Crippa A. Jose, Zuardi W. Antonio, Nardi E. Antonio and Silva C. Adriana, Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol: A Chemical Compound of Cannabis sativa, CNS & Neurological Disorders - Drug Targets 2014; 13 (6) . https://dx.doi.org/10.2174/1871527313666140612114838
DOI https://dx.doi.org/10.2174/1871527313666140612114838 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
“Liking” and “Wanting” Linked to Reward Deficiency Syndrome (RDS): Hypothesizing Differential Responsivity in Brain Reward Circuitry
Current Pharmaceutical Design Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Synthesis of a Novel Curcumin Derivative as a Potential Imaging Probe in Alzheimer’s Disease Imaging
Current Alzheimer Research The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design Viral Product Trafficking to Mitochondria, Mechanisms and Roles in Pathogenesis
Infectious Disorders - Drug Targets Glucocorticoids and Vascular Reactivity
Current Vascular Pharmacology Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Editorial: Pain in Dementia: A Distressing Combination of Several Factors
Current Alzheimer Research Self-inflicted Bilateral Ocular Perforation in an Adolescent Patient with Major Depressive Disorder and Borderline Personality Traits
Adolescent Psychiatry Oestrogen-A Protective Factor in Schizophrenia?
Current Psychiatry Reviews Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Circadian Rhythms, Melatonin and Depression
Current Pharmaceutical Design 9.4T Magnetic Resonance Imaging of the Mouse Circle of Willis Enables Serial Characterization of Flow-Induced Vascular Remodeling by Computational Fluid Dynamics
Current Neurovascular Research Novel Etomidate Derivatives
Current Pharmaceutical Design MicroRNAs-based Therapy: A Novel and Promising Strategy for Cancer Treatment
MicroRNA In Search of Novel AMPA Potentiators
Recent Patents on CNS Drug Discovery (Discontinued) Interpersonal-Psychological Precursors to Suicidal Behavior: A Theory of Attempted and Completed Suicide
Current Psychiatry Reviews p-Benzoquinone as a Privileged Scaffold of Pharmacological Significance: A Review
Mini-Reviews in Medicinal Chemistry An Overview of the Chemistry and Pharmacological Potentials of Furanones Skeletons
Current Organic Chemistry Towards Next Generation Adenosine A<sub>2A</sub> Receptor Antagonists
Current Medicinal Chemistry